Additional Results of POSLUMA (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO : vimarsana.com

Sub-group analysis from Blue Earth Diagnostics’ Phase 3 LIGHTHOUSE trial highlights POSLUMA utility to guide treatment selection and potentially avoid futile surgery

Related Keywords

Germany , Munich , Bayern , Davide Gauden , Garya Ulaner , Scintomics Gmb , Philliph Kuo , Los Angeles , University Of Arizona , Study Group , Drug Administration , University Of Southern California , Solutions Inc , Hoag Family Cancer Institute , Technical University Of Munich , A Siemens Healthineers Company , Blue Earth Diagnostics , True Positive , Detection Rate , Medical Imaging , Chief Executive Officer , Blue Earth , Siemens Healthineers , Newly Diagnosed High Risk Prostate Cancer , Negative Conventional Imaging , Biomedical Engineering , Southern California , Radiohybrid Prostate Specific Membrane Antigen , Prostate Specific Membrane Antigen , Prostate Specific Membrane Antigen Targeted , Technical University , Scintomics Gmbh , Important Safety Information About , Image Misinterpretation , Suspected Prostate Cancer Recurrence ,